NeuroScientific Says Review of Biotechnology Firm's Data Shows 'Promising' Results for StemSmart Therapy in Renal Transplants, Shares Fall 3%

MT Newswires Live

Aug 27

NeuroScientific Biopharmaceuticals (ASX:NSB) said that a review of historical studies, data, findings, and publications following the acquisition of Isopogen WA found that StemSmart mesenchymal stromal cell (MSC) therapy showed "promising" results in two early studies in renal transplantation, according to a Wednesday Australian bourse filing.

Isopogen WA is the holder of StemSmart, a patented stem cell technology.

The studies support further clinical development and the potential of StemSmart MSC in both preventing and treating graft failure and rejection, the firm noted.

A case series of 10 adult patients with treatment-refractory acute renal rejection following kidney transplants were treated with StemSmart MSC as a salvage and adjunctive therapy. Eight out of 10 patients retained their kidney following the infusion.

A second study undertaken in 12 adults undergoing deceased-donor renal transplantation showed that StemSmart MSC infusion was well tolerated and safe, and the results were "encouraging" for an improvement in delayed graft function immediately post-transplant.

The firm's shares fell over 3% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2562799788"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562799788\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562799788?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-27 13:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562799788","market":"sg","top_or_hot":-1,"title":"NeuroScientific Says Review of Biotechnology Firm's Data Shows 'Promising' Results for StemSmart Therapy in Renal Transplants, Shares Fall 3%","media":"MT Newswires Live","content":"<html><body><p> NeuroScientific Biopharmaceuticals (ASX:NSB) said that a review of historical studies, data, findings, and publications following the acquisition of Isopogen WA found that StemSmart mesenchymal stromal cell (MSC) therapy showed \"promising\" results in two early studies in renal transplantation, according to a Wednesday Australian bourse filing.</p><p>Isopogen WA is the holder of StemSmart, a patented stem cell technology.</p><p>The studies support further clinical development and the potential of StemSmart <a href=\"https://laohu8.com/S/NPW.SI\">MSC</a> in both preventing and treating graft failure and rejection, the firm noted.</p><p>A case series of 10 adult patients with treatment-refractory acute renal rejection following kidney transplants were treated with StemSmart MSC as a salvage and adjunctive therapy. Eight out of 10 patients retained their kidney following the infusion.</p><p>A second study undertaken in 12 adults undergoing deceased-donor renal transplantation showed that StemSmart MSC infusion was well tolerated and safe, and the results were \"encouraging\" for an improvement in delayed graft function immediately post-transplant.</p><p>The firm's shares fell over 3% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeuroScientific Says Review of Biotechnology Firm's Data Shows 'Promising' Results for StemSmart Therapy in Renal Transplants, Shares Fall 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuroScientific Says Review of Biotechnology Firm's Data Shows 'Promising' Results for StemSmart Therapy in Renal Transplants, Shares Fall 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-27 13:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> NeuroScientific Biopharmaceuticals (ASX:NSB) said that a review of historical studies, data, findings, and publications following the acquisition of Isopogen WA found that StemSmart mesenchymal stromal cell (MSC) therapy showed \"promising\" results in two early studies in renal transplantation, according to a Wednesday Australian bourse filing.</p><p>Isopogen WA is the holder of StemSmart, a patented stem cell technology.</p><p>The studies support further clinical development and the potential of StemSmart <a href=\"https://laohu8.com/S/NPW.SI\">MSC</a> in both preventing and treating graft failure and rejection, the firm noted.</p><p>A case series of 10 adult patients with treatment-refractory acute renal rejection following kidney transplants were treated with StemSmart MSC as a salvage and adjunctive therapy. Eight out of 10 patients retained their kidney following the infusion.</p><p>A second study undertaken in 12 adults undergoing deceased-donor renal transplantation showed that StemSmart MSC infusion was well tolerated and safe, and the results were \"encouraging\" for an improvement in delayed graft function immediately post-transplant.</p><p>The firm's shares fell over 3% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSC","symbol_name":"新濠影汇","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2562799788","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562799788","pubTimestamp":1756271798,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"NeuroScientific Biopharmaceuticals  said that a review of historical studies, data, findings, and publications following the acquisition of Isopogen WA found that StemSmart mesenchymal stromal cell  therapy showed \"promising\" results in two early studies in renal transplantation, according to a Wednesday Australian bourse filing.Isopogen WA is the holder of StemSmart, a patented stem cell technology.The studies support further clinical development and the potential of StemSmart MSC in both preventing and treating graft failure and rejection, the firm noted.A case series of 10 adult patients with treatment-refractory acute renal rejection following kidney transplants were treated with StemSmart MSC as a salvage and adjunctive therapy. Eight out of 10 patients retained their kidney following the infusion.A second study undertaken in 12 adults undergoing deceased-donor renal transplantation showed that StemSmart MSC infusion was well tolerated and safe, and the results were \"encouraging\" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MSC":"新濠影汇","BK4575":"芯片概念","BK4150":"赌场与赌博","NSB.AU":"NEUROSCIENTIFIC BIOPHARMACEU","BK7067":"生物科技"},"translate_title":"NeuroScientific表示，对生物技术公司数据的审查显示StemSmart疗法在肾移植中的结果“有希望”，股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSC":1,"NSB.AU":0.9},"content_text":"NeuroScientific Biopharmaceuticals (ASX:NSB) said that a review of historical studies, data, findings, and publications following the acquisition of Isopogen WA found that StemSmart mesenchymal stromal cell (MSC) therapy showed \"promising\" results in two early studies in renal transplantation, according to a Wednesday Australian bourse filing.Isopogen WA is the holder of StemSmart, a patented stem cell technology.The studies support further clinical development and the potential of StemSmart MSC in both preventing and treating graft failure and rejection, the firm noted.A case series of 10 adult patients with treatment-refractory acute renal rejection following kidney transplants were treated with StemSmart MSC as a salvage and adjunctive therapy. Eight out of 10 patients retained their kidney following the infusion.A second study undertaken in 12 adults undergoing deceased-donor renal transplantation showed that StemSmart MSC infusion was well tolerated and safe, and the results were \"encouraging\" for an improvement in delayed graft function immediately post-transplant.The firm's shares fell over 3% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}